Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia (RBSNAAMCL)

Patients diagnosed with acute myeloid leukemia in the Second Hospital of Shanxi Medical University were selected and divided into the newly diagnosed group, the relapsed group, the complete remission group as the experimental group, and the healthy physical examination subjects as the control group. The relationship between IL-1β, catecholamine and norkephalin in peripheral blood of the experimental group and the control group was observed. According to the literature, the experimental group was significantly higher than the control group. In the experimental group, the newly diagnosed group was higher than the relapse group, and the relapse group was higher than the complete remission group, and the correlation was positive, and the difference was statistically significant.

Study Overview

• Status: Not yet recruiting
• Conditions: AML
• Intervention / Treatment: Diagnostic test: Enzyme-linked immunosorbent assay

• Study Type: Observational
• Enrollment (Estimated): 80

Contacts and Locations

Study Locations

• China
  • Shanxi
    • Taiyuan, Shanxi, China, 030001
      • Second Hospital of Shanxi Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients in the Second Hospital of Shanxi Medical University from June 2022 to November 2023

Description

Inclusion Criteria:

• In accordance with adult acute myeloid leukemia (non-acute promyelocytic leukemia)The diagnostic criteria for AML in the Chinese Diagnosis and Treatment Guidelines (2017 edition); ②Leukocyte count ≤ 25×109/L;

  • No treatment has been received in the past 6 months.

    • None of the candidates are related and known this study, and sign the informed consent.

Exclusion Criteria:

• Patients who are allergic to the drugs used in this study;

  • People with mental illness or cognitive impairment;

    • Patients with infectious diseases; ④Patients with severe heart, liver, kidney and other organ function lesions; ⑤ Combined with other malignant swelling. The tumor.

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
the control group	Diagnostic test: Enzyme-linked immunosorbent assay; Serum N/OFQ , IL-1β and NE levels were detected.
the newly diagnosed group	Diagnostic test: Enzyme-linked immunosorbent assay; Serum N/OFQ , IL-1β and NE levels were detected.
the relapsed group	Diagnostic test: Enzyme-linked immunosorbent assay; Serum N/OFQ , IL-1β and NE levels were detected.
the complete remission group	Diagnostic test: Enzyme-linked immunosorbent assay; Serum N/OFQ , IL-1β and NE levels were detected.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
N/OFQ	Serum N/OFQ levels	24 hours
NE	Serum NE levels	24 hours
IL-1β	Serum IL-1β levels	24 hours

Collaborators and Investigators

• Sponsor: Second Hospital of Shanxi Medical University

Study record dates

Study Major Dates

• Study Start (Estimated): June 20, 2024
• Primary Completion (Estimated): November 30, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: June 16, 2024
• First Submitted That Met QC Criteria: June 16, 2024
• First Posted (Actual): June 21, 2024

Study Record Updates

• Last Update Posted (Actual): June 21, 2024
• Last Update Submitted That Met QC Criteria: June 16, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Leukemia
• Other Study ID Numbers: Hanyi20240408

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No